


Michael Kinch
Pharmacological Sciences



Research interests

Dr. Kinch has been analyzing key trends in the research and development of new medicines, vaccines, and medical devices. This work works at the interface amongst science, medicines, law and business. His work also extends to leadership of the Center for Research Innovation in Biotechnology, a joint program between Stony Brook University and Purdue University as well as leadership of the CrisisScience Collaborative, a multi-institutional thinktank of scientists, who help identify and prevent future challenges.

Qualifications

PhD in Immunology, Duke University
Aug 15 1989 → Aug 15 1993
Award Date: Aug 15 1993

Bachelor, Molecular Genetics, The Ohio State University
Sep 15 1985 → Sep 15 1989
Award Date: Jun 7 1989

Employment

Pharmacological Sciences

Stony Brook University
Aug 1 2024 → present

Professor

Office for Research and Innovation
Stony Brook University
Aug 1 2024 → Jul 18 2026

Chief Innovation Officer

Stony Brook University
United States
Aug 1 2024 → present

Executive Dean of Sciences

Long Island University
United States
Jul 1 2022 → Jul 31 2024

Associate Vice Chancellor

Washington University St. Louis
United States
Aug 1 2014 → Jun 30 2022

Managing Director, Yale Center for Molecular Discovery

Yale University
United States
Dec 2 2010 → Jul 30 2014

Vice President for Research & Development

Functional Genetics, Inc.
Gaithersburg, MD 20878, United States
Aug 15 2006 → Dec 1 2010

Instructor

Johns Hopkins University
United States
Aug 15 2006 → Dec 1 2010

Chair, Departments of Cancer Biology & Translational Sciences

MedImmune
Gaithersburg, United States
Dec 19 2001 → Aug 14 2006

Associate Professor (with tenure)

Purdue University
United States
Jul 1 1996 → Dec 18 2001

Post-Doctoral Fellow

University of North Carolina at Chapel Hill
United States
Aug 16 1993 → Jun 30 1996

Research outputs

Drug type contributions to pharmaceutical innovation: A USA–China comparative analysis

Kinch, M. S., Alwani, A., Schwartz, T. & Kraft, Z., Sep 2026, In: Drug Discovery Today. 31, 5, 104760.

2025 In Review: Trends in Pharmaceutical Innovation

Kinch, M. S., Kraft, Z. & Schwartz, T., Mar 2026, In: Drug Discovery Today. 31, 2, 104610.

Geopolitical contributions to pharmaceutical innovation

Kinch, M. S., Alawi, A., Schwartz, T. & Kraft, Z., Jan 2026, In: Drug Discovery Today. 31, 1, 104588.

The Untold Story of the Scientists Who Confronted COVID-19: BEHIND THE MASK

Kinch, M. S., 2026, *Coresource 4*. Purdue University Press, p. 1-298 298 p.

Ignore at Your Own Risk: American Academic Contributions to the Development of Small Molecule Therapeutics

Kinch, M. S., Sep 2025, In: Drug Discovery Today. 30, 9, 104438.

Target & Mechanism Selection in Pharmaceutical Innovation: A Source for Concern or Optimism?

Kinch, M. S., Kraft, Z. & Schwartz, T., May 2025, In: Drug Discovery Today. 30, 5, 104361.

2024 in Review: FDA Approval of New Medicines

Kinch, M. S., Kraft, Z. & Schwartz, T., Apr 2025, In: Drug Discovery Today. 30, 4, 104334.

2023 in review: FDA approvals of new medicines

Kinch, M. S., Kraft, Z. & Schwartz, T., May 2024, In: Drug Discovery Today. 29, 5, 103966.

Antibiotic Development: Lessons from the Past and Future Opportunities

Kinch, M. S., Kraft, Z. & Schwartz, T., May 2024, In: Pharmaceutical Research. 41, 5, p. 839-848 10 p.

WANTED DEAD OR ALIVE: New Thinking to Incentivize Drug Development

Kinch, M. S., Feb 2024, In: Pharmaceutical Research. 41, 2, p. 199-202 4 p.

Fiduciary responsibility

Kinch, M. S., Nov 2023, In: Drug Discovery Today. 28, 11, 103794.

The pharmaceutical innovator's dilemma

Kinch, M. S., Sep 2023, In: Drug Discovery Today. 28, 9, 103699.

2022 in review: FDA approvals of new medicines

Kinch, M. S., Kraft, Z. & Schwartz, T., Aug 2023, In: Drug Discovery Today. 28, 8, 103622.

Keeping apace on the pharmaceutical treadmill

Kinch, M. S., Jul 2023, In: Drug Discovery Today. 28, 7, 103630.

Immunoconjugates and bispecific antibodies: Trends in therapeutic success and commercial focus

Kinch, M. S., Kraft, Z. & Schwartz, T., Mar 2023, In: Drug Discovery Today. 28, 3, 103462.

Monoclonal antibodies: Trends in therapeutic success and commercial focus

Kinch, M. S., Kraft, Z. & Schwartz, T., Jan 2023, In: Drug Discovery Today. 28, 1, 103415.

A Novel Innovation and Entrepreneurship (I&E) Training Program for Biomedical Research Trainees

Grailer, J. G., Alhallak, K., Antes, A. L., Kinch, M. S., Woods, L., Toker, E. & Garbutt, J. M., Sep 1 2022, In: Academic Medicine. 97, 9, p. 1335-1340 6 p.

2021 in review: FDA approvals of new medicines

Kinch, M. S., Kraft, Z. & Schwartz, T., Aug 2022, In: Drug Discovery Today. 27, 8, p. 2057-2064 8 p.

Patents, trade secrets and pricing

Kinch, M. S. & Mackin, S., Jun 2022, In: Drug Discovery Today. 27, 6, p. 1531-1532 2 p.

A reconsideration of university gap funds for promoting biomedical entrepreneurship

Hall, E. G., Krenning, T. M., Reardon, R. J., Toker, E. & Kinch, M. S., Jan 31 2022, In: Journal of Clinical and Translational Science. 6, 1, e28.

2020 in review: FDA approvals of new medicines

Kinch, M. S., Kraft, Z. & Schwartz, T., Dec 2021, In: Drug Discovery Today. 26, 12, p. 2794-2799 6 p.

Sources of innovation for new medicines: questions of sustainability

Kinch, M. S., Kraft, Z. & Schwartz, T., Jan 2021, In: Drug Discovery Today. 26, 1, p. 240-247 8 p.

Rising Academic Contributions to Drug Development: Evidence of Vigor or Trauma?

Kinch, M. S., Horn, C., Kraft, Z. & Schwartz, T., Dec 11 2020, In: ACS Pharmacology and Translational Science. 3, 6, p. 1427-1429 3 p.

2019 in review: FDA approvals of new medicines

Kinch, M. S., Kraft, Z. & Schwartz, T., Nov 2020, In: Drug Discovery Today. 25, 11, p. 1923-1929 7 p.

Expanding roles for academic entrepreneurship in drug discovery

Kinch, M. S., Horn, C., Kraft, Z. & Schwartz, T., Nov 2020, In: Drug Discovery Today. 25, 11, p. 1905-1909 5 p.

Oh, the Frustration of Antibodies!

Kinch, M. S., Oct 9 2020, In: ACS Pharmacology and Translational Science. 3, 5, p. 1035-1036 2 p.

2018 in review: FDA approvals of new molecular entities

Kinch, M. S. & Griesenauer, R. H., Sep 2019, In: Drug Discovery Today. 24, 9, p. 1710-1714 5 p.

Assessing the public landscape of clinical-stage pharmaceuticals through freely available online databases

Griesenauer, R. H., Schillebeeckx, C. & Kinch, M. S., Apr 2019, In: Drug Discovery Today. 24, 4, p. 1010-1016 7 p.

Lost medicines: a longer view of the pharmaceutical industry with the potential to reinvigorate discovery

Kinch, M. S., Kinch, G. A. & Griesenauer, R. H., Feb 2019, In: Drug Discovery Today. 24, 2, p. 382-389 8 p.

CDEK: Clinical Drug Experience Knowledgebase

Griesenauer, R. H., Schillebeeckx, C. & Kinch, M. S., 2019, In: Database. 2019, 1, baz087.

2017 in review: FDA approvals of new molecular entities

Kinch, M. S. & Griesenauer, R. H., Aug 2018, In: Drug Discovery Today. 23, 8, p. 1469-1473 5 p.

An overview of FDA-approved vaccines & their innovators

Griesenauer, R. H. & Kinch, M. S., Dec 2 2017, In: Expert Review of Vaccines. 16, 12, p. 1253-1266 14 p.

NIH Support for FDA-Approved Medicines

Griesenauer, R. H., Moore, R. & Kinch, M. S., Nov 16 2017, In: Cell Chemical Biology. 24, 11, p. 1315-1316 2 p.

2016 in review: FDA approvals of new molecular entities

Griesenauer, R. H. & Kinch, M. S., Nov 2017, In: Drug Discovery Today. 22, 11, p. 1593-1597 5 p.

Food and microbiota in the FDA regulatory framework

Green, J. M., Barratt, M. J., Kinch, M. & Gordon, J. I., Jul 7 2017, In: Science. 357, 6346, p. 39-40 2 p.

Analysis of FDA-approved imaging agents

Kinch, M. S. & Woodard, P. K., Jul 2017, In: Drug Discovery Today. 22, 7, p. 1077-1083 7 p.

2014 in review: FDA approval of new drugs

Kinch, M. S., Apr 1 2017, In: Drug Discovery Today. 22, 4, p. 620-624 5 p.

2015 in review: FDA approval of new drugs

Kinch, M. S., Jul 1 2016, In: Drug Discovery Today. 21, 7, p. 1046-1050 5 p.

An analysis of FDA-approved drugs for cardiovascular diseases

Kinch, M. S., Surovtseva, Y. & Hoyer, D., Jan 1 2016, In: Drug Discovery Today. 21, 1, p. 1-4 4 p.

An analysis of FDA-approved drugs: Natural products and their derivatives

Patridge, E., Gareiss, P., Kinch, M. S. & Hoyer, D., 2016, In: Drug Discovery Today. 21, 2, p. 204-207 4 p.

Innovator Organizations in New Drug Development: Assessing the Sustainability of the Biopharmaceutical Industry

Kinch, M. S. & Moore, R., 2016, In: Cell Chemical Biology. 23, 6, p. 644-653 10 p.

Enhancing the Quality of Patent Claims Directed to Biologics with Biophysical Evidence

Lathrop, B. K. & Kinch, M. S., Dec 2015, In: Biotechnology Law Report. 34, 6, p. 213-235 23 p.

New drug discovery: Extraordinary opportunities in an uncertain time

Kinch, M. S. & Flath, R., Nov 1 2015, In: Drug Discovery Today. 20, 11, p. 1288-1292 5 p.

A history of drug development in four acts

Kinch, M. S. & Hoyer, D., Oct 1 2015, In: Drug Discovery Today. 20, 10, p. 1163-1168 6 p., 1609.

An analysis of original research contributions toward FDA-approved drugs

Patridge, E. V., Gareiss, P. C., Kinch, M. S. & Hoyer, D. W., Oct 2015, In: Drug Discovery Today. 20, 10, p. 1182-1187 6 p.

An analysis of FDA-approved drugs for neurological disorders

Kinch, M. S., Sep 9 2015, In: Drug Discovery Today. 20, 9, p. 1040-1043 4 p.

An analysis of FDA-approved drugs for inflammation and autoimmune diseases

Kinch, M. S. & Merkel, J., Aug 1 2015, In: Drug Discovery Today. 20, 8, p. 920-923 4 p., 1582.

Target selection for FDA-approved medicines

Kinch, M. S., Hoyer, D., Patridge, E. & Plummer, M., Jul 9 2015, In: Drug Discovery Today. 20, 7, p. 784-789 6 p., 1532.

Sources of innovation: An assessment of intellectual property

Kinch, M. S. & Raffo, J., May 1 2015, In: Drug Discovery Today. 20, 5, p. 500-504 5 p.

An overview of FDA-approved biologics medicines

Kinch, M. S., Apr 1 2015, In: Drug Discovery Today. 20, 4, p. 393-398 6 p.

An analysis of FDA-approved drugs for psychiatric disorders

Kinch, M. S. & Patridge, E., Mar 2015, In: Drug Discovery Today. 20, 3, p. 292-295 4 p.

Post-approval fate of pharmaceutical companies

Kinch, M. S., Feb 2015, In: Drug Discovery Today. 20, 2, p. 170-174 5 p.

An analysis of FDA-approved drugs for pain and anesthesia

Kinch, M. S., Jan 2015, In: Drug Discovery Today. 20, 1, p. 3-6 4 p.

An analysis of FDA-approved drugs for metabolic diseases

Kinch, M. S., Umlauf, S. & Plummer, M., 2015, In: Drug Discovery Today. 20, 6, p. 648-651 4 p.

An analysis of FDA-approved drugs for oncology

Kinch, M. S., Dec 2014, In: Drug Discovery Today. 19, 12, p. 1831-1835 5 p.

The rise (and decline?) of biotechnology

Kinch, M. S., Nov 2014, In: Drug Discovery Today. 19, 11, p. 1686-1690 5 p.

Trends in pharmaceutical targeting of clinical indications: 1930-2013

Kinch, M. S., Merkel, J. & Umlauf, S., Nov 2014, In: Drug Discovery Today. 19, 11, p. 1682-1685 4 p.

An analysis of FDA-approved drugs for infectious disease: HIV/AIDS drugs

Kinch, M. S. & Patridge, E., Oct 2014, In: Drug Discovery Today. 19, 10, p. 1510-1513 4 p.

An analysis of FDA-approved drugs for infectious disease: Antibacterial agents

Kinch, M. S., Patridge, E., Plummer, M. & Hoyer, D., Sep 2014, In: Drug Discovery Today. 19, 9, p. 1283-1287 5 p.

An overview of FDA-approved new molecular entities: 1827-2013

Kinch, M. S., Haynesworth, A., Kinch, S. L. & Hoyer, D., Aug 2014, In: Drug Discovery Today. 19, 8, p. 1033-1039 7 p.

Dual targeting of EphA2 and ER restores Tamoxifen sensitivity in ER/EphA2-positive breast cancer

Gökmen-Polar, Y., Toroni, R. A., Hocevar, B. A., Badve, S., Zhao, Q., Shen, C., Bruckheimer, E., Kinch, M. S. & Miller, K. D., Jun 2011, In: Breast Cancer Research and Treatment. 127, 2, p. 375-384 10 p.

Antiviral activity of a small-molecule inhibitor of filovirus infection

Warren, T. K., Warfield, K. L., Wells, J., Enterlein, S., Smith, M., Ruthel, G., Yunus, A. S., Kinch, M. S., Goldblatt, M., Aman, M. J. & Bavari, S., May 2010, In: Antimicrobial Agents and Chemotherapy. 54, 5, p. 2152-2159 8 p.

Identification of annexin A13 as a regulator of chemotherapy resistance using random homozygous gene perturbation

Reiske, H., Sui, B., Ung-Medoff, H., Donahue, R., Li, W. B., Goldblatt, M., Li, L. & Kinch, M. S., Apr 2010, In: Analytical and Quantitative Cytology and Histology. 32, 2, p. 61-69 9 p.

Antibody targeting of TSG101 on influenza-infected cells

Bonavia, A., Diaz, L. S., Santos, D., Cassella, J., Fesseha, Z., Bamba, D., Sui, B., Li, W. B., Duan, R., Goldblatt, M., Kinch, M. S., Chen, L. M., Donis, R. O. & Goldblatt, M., 2010, In: Virus Adaptation and Treatment. 2, 1, p. 147-157 11 p.

Development of FGI-106 as a broad-spectrum therapeutic with activity against members of the family Bunyaviridae

Smith, D. R., Ogg, M., Garrison, A., Yunus, A., Honko, A., Johnson, J., Olinger, G., Hensley, L. E. & Kinch, M. S., 2010, In: Virus Adaptation and Treatment. 2, 1, p. 9-20 12 p.

TSG101 exposure on the surface of HIV-1 infected cells: Implications for monoclonal antibody therapy for HIV/AIDS

Diaz, L., Mao, H., Zhou, Y., Kohli, M., Cassella, J., Santos, D., Fesseha, Z., Weng, K., Chen, H., Bamba, D., Marks, J. D., Goldblatt, M. & Kinch, M., 2010, In: American Journal of Translational Research. 2, 4, p. 368-380 13 p.

Enhancement in specific CD8⁺ T cell recognition of EphA2⁺ tumors in vitro and in vivo after treatment with ligand agonists

Wesa, A. K., Herrem, C. J., Mandic, M., Taylor, J. L., Vasquez, C., Kawabe, M., Tatsumi, T., Leibowitz, M. S., Finke, J. H., Bukowski, R. M., Bruckheimer, E., Kinch, M. S. & Storkus, W. J., Dec 1 2009, In: Journal of Immunology. 181, 11, p. 7721-7727 7 p.

Development of a broad-spectrum antiviral with activity against Ebola virus

Aman, M. J., Kinch, M. S., Warfield, K., Warren, T., Yunus, A., Enterlein, S., Stavale, E., Wang, P., Chang, S., Tang, Q., Porter, K., Goldblatt, M. & Bavari, S., Sep 2009, In: Antiviral Research. 83, 3, p. 245-251 7 p.

Antibody-dependent cell-mediated cytotoxicity effector-enhanced EphA2 agonist monoclonal antibody demonstrates potent activity against human tumors

Bruckheimer, E. M., Fazenbaker, C. A., Gallagher, S., Mulgrew, K., Fuhrmann, S., Coffman, K. T., Walsh, W., Ready, S., Cook, K., Damschroder, M., Kinch, M., Kiener, P. A., Woods, R., Gao, C., Dall'Acqua, W., Wu, H. & Coats, S., Jun 2009, In: Neoplasia. 11, 6, p. 509-517 9 p.

The use of Random Homozygous Gene Perturbation to identify novel host-oriented targets for influenza

Sui, B., Bamba, D., Weng, K., Ung, H., Chang, S., Van Dyke, J., Goldblatt, M., Duan, R., Kinch, M. S. & Li, W. B., May 10 2009, In: Virology. 387, 2, p. 473-481 9 p.

FGI-104: A broad-spectrum small molecule inhibitor of viral infection

Kinch, M. S., Yunus, A. S., Lear, C., Mao, H., Chen, H., Fesseha, Z., Luo, G., Nelson, E. A., Li, L., Huang, Z., Murray, M., Ellis, W. Y., Hensley, L., Christopher-Hennings, J., Olinger, G. G. & Goldblatt, M., 2009, In: American Journal of Translational Research. 1, 1, p. 87-98 12 p.

Function-first approaches to improve target identification in cancer

Kinch, M. S., Kohli, M., Goldblatt, M. & Li, W. B., 2009, In: *Future Oncology*. 5, 5, p. 617-623 7 p.

Identification of novel host-oriented targets for Human Immunodeficiency Virus type 1 using Random Homozygous Gene Perturbation

Mao, H., Chen, H., Fesseha, Z., Chang, S., Ung-Medoff, H., Van Dyke, J., Kohli, M., Li, W. B., Goldblatt, M. & Kinch, M. S., 2009, In: *Virology Journal*. 6, 154.

Identification of PTCH1 requirement for influenza virus using random homozygous gene perturbation

Li, W. B., Zhu, J., Hart, B., Sui, B., Weng, K., Chang, S., Geiger, R., Torremorell, M., Mileham, A., Gladney, C., Mellancamp, M. A., Li, L., Yunus, A., Goldblatt, M. & Kinch, M. S., 2009, In: *American Journal of Translational Research*. 1, 3, p. 259-266 8 p.

A human antibody-drug conjugate targeting EphA2 inhibits tumor growth in vivo

Jackson, D., Gooya, J., Mao, S., Kinneer, K., Xu, L., Camara, M., Fazenbaker, C., Fleming, R., Swamynathan, S., Meyer, D., Senter, P. D., Gao, C., Wu, H., Kinch, M., Coats, S., Kiener, P. A. & Tice, D. A., Nov 15 2008, In: *Cancer Research*. 68, 22, p. 9367-9374 8 p.

Tumor-selective response to antibody-mediated targeting of $\alpha_v\beta_3$ integrin in ovarian cancer

Landen, C. N., Kim, T. J., Lin, Y. G., Merritt, W. M., Kamat, A. A., Han, L. Y., Spannuth, W. A., Nick, A. M., Jennings, N. B., Kinch, M. S., Tice, D. & Sood, A. K., Nov 2008, In: *Neoplasia*. 10, 11, p. 1259-1267 9 p.

EphA2 overexpression promotes ovarian cancer growth

Lu, C., Shahzad, M. M. K., Wang, H., Landen, C. N., Kim, S. W., Allen, J., Nick, A. M., Jennings, N., Kinch, M. S., Bar-Eli, M. & Sood, A. K., Jul 2008, In: *Cancer Biology and Therapy*. 7, 7, p. 1098-1103 6 p.

Selective targeting and potent control of tumor growth using an EphA2/CD3-bispecific single-chain antibody construct

Hammond, S. A., Lutterbuese, R., Roff, S., Lutterbuese, P., Schlereth, B., Bruckheimer, E., Kinch, M. S., Coats, S., Baeuerle, P. A., Kufer, P. & Kiener, P. A., Apr 15 2007, In: *Cancer Research*. 67, 8, p. 3927-3935 9 p.

EphA2 overexpression is associated with angiogenesis in ovarian cancer

Lin, Y. G., Han, L. Y., Kamat, A. A., Merritt, W. M., Landen, C. N., Deavers, M. T., Fletcher, M. S., Urbauer, D. L., Kinch, M. S. & Sood, A. K., Jan 15 2007, In: *Cancer*. 109, 2, p. 332-340 9 p.

Direct targeting of $\alpha_v\beta_3$ integrin on tumor cells with a monoclonal antibody, Abegrin[™]

Mulgrew, K., Kinneer, K., Yao, X. T., Ward, B. K., Damschroder, M. M., Walsh, B., Mao, S. Y., Gao, C., Kiener, P. A., Coats, S., Kinch, M. S. & Tice, D. A., Dec 2006, In: *Molecular Cancer Therapeutics*. 5, 12, p. 3122-3129 8 p.

Efficacy and antivasular effects of EphA2 reduction with an agonistic antibody in ovarian cancer

Landen, C. N., Lu, C., Han, L. Y., Coffman, K. T., Bruckheimer, E., Halder, J., Mangala, L. S., Merritt, W. M., Lin, Y. G., Gao, C., Schmandt, R., Kamat, A. A., Li, Y., Thaker, P., Gershenson, D. M., Parikh, N. U., Gallick, G. E., Kinch, M. S. & Sood, A. K., Nov 1 2006, In: *Journal of the National Cancer Institute*. 98, 21, p. 1558-1570 13 p.

Analysis of EphA2 expression and mutant p53 in ovarian carcinoma

Merritt, W. M., Thaker, P. H., Landen, C. N., Deavers, M. T., Fletcher, M. S., Lin, Y. G., Han, L. Y., Kamat, A. A., Schmandt, R., Gershenson, D. M., Kinch, M. S. & Sood, A. K., Oct 2006, In: *Cancer Biology and Therapy*. 5, 10, p. 1357-1360 4 p.

Expression and purification of the intact cytoplasmic domain of the human ephrin receptor A2 tyrosine kinase in *Escherichia coli*

Zabell, K. M., Laurence, J. S., Kinch, M. S., Knapp, D. W. & Stauffacher, C. V., May 2006, In: *Protein Expression and Purification*. 47, 1, p. 210-216 7 p.

VE-cadherin regulates EphA2 in aggressive melanoma cells through a novel signaling pathway: Implications for vasculogenic mimicry

Hess, A. R., Seftor, E. A., Gruman, L. M., Kinch, M. S., Seftor, R. E. B. & Hendrix, M. J. C., Feb 2006, In: Cancer Biology and Therapy. 5, 2, p. 228-233 6 p.

Expression of EphA2 and Ephrin A-1 in carcinoma of the urinary bladder

Abraham, S., Knapp, D. W., Cheng, L., Snyder, P. W., Mittal, S. K., Bangari, D. S., Kinch, M., Wu, L., Dhariwal, J. & Mohammed, S. I., Jan 15 2006, In: Clinical Cancer Research. 12, 2, p. 353-360 8 p.

EphA2 as a target for ovarian cancer therapy

Landen, C. N., Kinch, M. S. & Sood, A. K., Dec 2005, In: Expert Opinion on Therapeutic Targets. 9, 6, p. 1179-1187 9 p.

EphA2 as a glioma-associated antigen: A novel target for glioma vaccines

Hatano, M., Eguchi, J., Tatsumi, T., Kuwashima, N., Dusak, J. E., Kinch, M. S., Pollack, I. F., Hamilton, R. L., Storkus, W. J. & Okada, H., Aug 2005, In: Neoplasia. 7, 8, p. 717-722 6 p.

Expression of EphA2 is prognostic of disease-free interval and overall survival in surgically treated patients with renal cell carcinoma

Herrem, C. J., Tatsumi, T., Olson, K. S., Shirai, K., Finke, J. H., Bukowski, R. M., Zhou, M., Richmond, A. L., Derweesh, I., Kinch, M. S. & Storkus, W. J., Jan 1 2005, In: Clinical Cancer Research. 11, 1, p. 226-231 6 p.

Decreased tumorigenic potential of EphA2-overexpressing breast cancer cells following treatment with adenoviral vectors that express EphrinA1

Noblitt, L. W., Bangari, D. S., Shukla, S., Knapp, D. W., Mohammed, S., Kinch, M. S. & Mittal, S. K., Nov 2004, In: Cancer Gene Therapy. 11, 11, p. 757-766 10 p.

EphA2 induction of fibronectin creates a permissive microenvironment for malignant cells

Hu, M., Carles-Kinch, K. L., Zelinski, D. P. & Kinch, M. S., Oct 2004, In: Molecular Cancer Research. 2, 10, p. 533-540 8 p.

EphA2 expression is associated with aggressive features in ovarian carcinoma

Thaker, P. H., Deavers, M., Celestino, J., Thornton, A., Fletcher, M. S., Landen, C. N., Kinch, M. S., Kiener, P. A. & Sood, A. K., Aug 1 2004, In: Clinical Cancer Research. 10, 15, p. 5145-5150 6 p.

Loss of 14-3-3 σ in Prostate Cancer and Its Precursors

Cheng, L., Pan, C. X., Zhang, J. T., Zhang, S., Kinch, M. S., Li, L., Baldrige, L. A., Wade, C., Hu, Z., Koch, M. O., Ulbright, T. M. & Eble, J. N., May 1 2004, In: Clinical Cancer Research. 10, 9, p. 3064-3068 5 p.

PC Cell-Derived Growth Factor Expression in Prostatic Intraepithelial Neoplasia and Prostatic Adenocarcinoma

Pan, C. X., Kinch, M. S., Kiener, P. A., Langermann, S., Serrero, G., Sun, L., Corvera, J., Sweeney, C. J., Li, L., Zhang, S., Baldrige, L. A., Jones, T. D., Koch, M. O., Ulbright, T. M., Eble, J. N. & Cheng, L., Feb 15 2004, In: Clinical Cancer Research. 10, 4, p. 1333-1337 5 p.

High-Level Expression of EphA2 Receptor Tyrosine Kinase in Prostatic Intraepithelial Neoplasia

Zeng, G., Hu, Z., Kinch, M. S., Pan, C. X., Flockhart, D. A., Kao, C., Gardner, T. A., Zhang, S., Li, L., Baldrige, L. A., Koch, M. O., Ulbright, T. M., Eble, J. N. & Cheng, L., Dec 2003, In: American Journal of Pathology. 163, 6, p. 2271-2276 6 p.

Ligand Binding Up-Regulates EphA2 Messenger RNA through the Mitogen-Activated Protein/Extracellular Signal-Regulated Kinase Pathway

Pratt, R. L. & Kinch, M. S., Dec 2003, In: Molecular Cancer Research. 1, 14, p. 1070-1076 7 p.

TEL, a Putative Tumor Suppressor, Induces Apoptosis and Represses Transcription of Bcl-X_L

Irvin, B. J., Wood, L. D., Wang, L., Fenrick, R., Sansam, C. G., Packham, G., Kinch, M., Yang, E. & Hiebert, S. W., Nov 21 2003, In: Journal of Biological Chemistry. 278, 47, p. 46378-46386 9 p.

Differential EphA2 Epitope Display on Normal versus Malignant Cells

Coffman, K. T., Hu, M., Carles-Kinch, K., Tice, D., Donacki, N., Munyon, K., Kifle, G., Woods, R., Langermann, S., Kiener, P. A. & Kinch, M. S., Nov 15 2003, In: Cancer Research. 63, 22, p. 7907-7912 6 p.

Disease stage variation in CD4+ and CD8+ T-cell reactivity to the receptor tyrosine kinase EphA2 in patients with renal cell carcinoma

Tatsumi, T., Herrem, C. J., Olson, W. C., Finke, J. H., Bukowski, R. M., Kinch, M. S., Ranieri, E. & Storkus, W. J., Aug 1 2003, In: Cancer Research. 63, 15, p. 4481-4489 9 p.

EphA2 overexpression decreases estrogen dependence and tamoxifen sensitivity

Lu, M., Miller, K. D., Gokmen-Polar, Y., Jeng, M. H. & Kinch, M. S., Jun 15 2003, In: Cancer Research. 63, 12, p. 3425-3429 5 p.

Differential regulation of EphA2 in normal and malignant cells

Walker-Daniels, J., Hess, A. R., Hendrix, M. J. C. & Kinch, M. S., Apr 1 2003, In: American Journal of Pathology. 162, 4, p. 1037-1042 6 p.

Predictive value of the EphA2 receptor tyrosine kinase in lung cancer recurrence and survival

Kinch, M. S., Moore, M. B. & Harpole, D. H., Feb 1 2003, In: Clinical Cancer Research. 9, 2, p. 613-618 6 p.

E-cadherin binding modulates EGF receptor activation

Fedor-Chaiken, M., Hein, P. W., Stewart, J. C., Brackenbury, R. & Kinch, M. S., 2003, In: Cell Communication and Adhesion. 10, 2, p. 105-118 14 p.

Overexpression and functional alterations of the EphA2 tyrosine kinase in cancer

Kinch, M. S. & Carles-Kinch, K., 2003, In: Clinical and Experimental Metastasis. 20, 1, p. 59-68 10 p.

c-Cbl-dependent EphA2 protein degradation is induced by ligand binding

Walker-Daniels, J., Riese, D. J. & Kinch, M. S., Nov 1 2002, In: Molecular Cancer Research. 1, 1, p. 79-87 9 p.

Activation of the EphA2 tyrosine kinase stimulates the MAP/ERK kinase signaling cascade

Pratt, R. L. & Kinch, M. S., Oct 31 2002, In: Oncogene. 21, 50, p. 7690-7699 10 p.

Regulation of the EphA2 kinase by the low molecular weight tyrosine phosphatase induces transformation

Kikawa, K. D., Vidale, D. R., Van Etten, R. L. & Kinch, M. S., Oct 18 2002, In: Journal of Biological Chemistry. 277, 42, p. 39274-39279 6 p.

Antibody targeting of the EphA2 tyrosine kinase inhibits malignant cell behavior

Carles-Kinch, K., Kilpatrick, K. E., Stewart, J. C. & Kinch, M. S., May 15 2002, In: Cancer Research. 62, 10, p. 2840-2847 8 p.

Estrogen and Myc negatively regulate expression of the EphA2 tyrosine kinase

Zelinski, D. P., Zantek, N. D., Walker-Daniels, J., Peters, M. A., Taparowsky, E. J. & Kinch, M. S., 2002, In: Journal of Cellular Biochemistry. 85, 4, p. 714-720 7 p.

Molecular regulation of tumor cell vasculogenic mimicry by tyrosine phosphorylation: Role of epithelial cell kinase (eck/epha2)

Hess, A. R., Seftor, E. A., Gardner, L. M. G., Carles-Kinch, K., Schneider, G. B., Seftor, R. E. B., Kinch, M. S. & Hendrix, M. J. C., Apr 15 2001, In: Cancer Research. 61, 8, p. 3250-3255 6 p.

EphA2 overexpression causes tumorigenesis of mammary epithelial cells

Zelinski, D. P., Zantek, N. D., Stewart, J. C., Irizarry, A. R. & Kinch, M. S., Mar 1 2001, In: Cancer Research. 61, 5, p. 2301-2306 6 p.

Analysis of cell migration

Zantek, N. D. & Kinch, M. S., 2001, In: *Methods in Cell Biology*. 63, p. 549-559 11 p.

Chapter 25 Analysis of cell migration

Dodge Zantek, N. & Kinch, M. S., 2001, *Cytometry: Part A. SUPPL. A* ed. Academic Press Inc., p. 549-559 11 p. (Methods in Cell Biology; vol. 63, no. SUPPL. A).

Cytometric analysis of cell contact and adhesion

Kinch, M. S., 2001, In: *Methods in Cell Biology*. 63, p. 599-612 14 p.

MCF-10A-NeoST: A new cell system for studying cell-ECM and cell-cell interactions in breast cancer

Dodge Zantek, N., Walker-Daniels, J., Stewart, J., Hansen, R. K., Robinson, D., Miao, H., Wang, B., Kung, H. J., Bissell, M. J. & Kinch, M. S., 2001, In: *Clinical Cancer Research*. 7, 11, p. 3640-3648 9 p.

Predicting the sites of metastases from lung cancer using molecular biologic markers

D'Amico, T. A., Aloia, T. A., Moore, M. B. H., Conlon, D. H., Herndon, J. E., Kinch, M. S. & Harpole, D. H., 2001, In: *The Annals of Thoracic Surgery*. 72, 4, p. 1144-1148 5 p.

Activation of EphA2 kinase suppresses integrin function and causes focal-adhesion-kinase dephosphorylation

Miao, H., Burnett, E., Kinch, M., Simon, E. & Wang, B., 2000, In: *Nature Cell Biology*. 2, 2, p. 62-69 8 p.

TEL, a putative tumor suppressor, modulates cell growth and cell morphology of Ras-transformed cells while repressing the transcription of stromelysin-1

Fenrick, R., Wang, L., Nip, J., Amann, J. M., Rooney, R. J., Walker-Daniels, J., Crawford, H. C., Hulboy, D. L., Kinch, M. S., Matrisian, L. M. & Hiebert, S. W., 2000, In: *Molecular and Cellular Biology*. 20, 16, p. 5828-5839 12 p.

E-cadherin regulates the function of the EphA2 receptor tyrosine kinase

Zantek, N. D., Azimi, M., Fedor-Chaiken, M., Wang, B., Brackenbury, R. & Kinch, M. S., Sep 1999, In: *Cell Growth and Differentiation*. 10, 9, p. 629-638 10 p.

Overexpression of the EphA2 tyrosine kinase in prostate cancer

Walker-Daniels, J., Coffman, K., Azimi, M., Rhim, J. S., Bostwick, D. G., Snyder, P., Kerns, B. J., Waters, D. J. & Kinch, M. S., 1999, In: *Prostate*. 41, 4, p. 275-280 6 p.

The engagement of β_1 integrins on promonocytic cells promotes phosphorylation of Syk and formation of a protein complex containing Lyn and β_1 integrin

Miller, L. A., Hong, J. J., Kinch, M. S., Harrison, M. L. & Geahlen, R. L., 1999, In: *European Journal of Immunology*. 29, 5, p. 1426-1434 9 p.

Workgroup 2: Human xenograft models of prostate cancer

Stearns, M. E., Ware, J. L., Agus, D. B., Chang, C. J., Fidler, I. J., Fife, R. S., Goode, R., Holmes, E., Kinch, M. S., Peehl, D. M., Pretlow, T. G. & Thalmann, G. N., Jun 15 1998, In: *Prostate*. 36, 1, p. 56-58 3 p.

Dynamic interactions of PTP μ with multiple cadherins in vivo

Brady-Kalnay, S. M., Mourtou, T., Nixon, J. P., Pietz, G. E., Kinch, M., Chen, H., Brackenbury, R., Rimm, D. L., Del Vecchio, R. L. & Tonks, N. K., Apr 6 1998, In: *Journal of Cell Biology*. 141, 1, p. 287-296 10 p.

Identification of tyrosine phosphorylated adhesion proteins in human cancer cells

Kinch, M. S., Kilpatrick, K. E. & Zhong, C., 1998, In: *Hybridoma*. 17, 3, p. 227-235 9 p.

A mechanism for trabecular meshwork cell retraction: Ethacrynic acid initiates the dephosphorylation of focal adhesion proteins

O'Brien, E. T., Kinch, M., Harding, T. W. & Epstein, D. L., Oct 1997, In: *Experimental Eye Research*. 65, 4, p. 471-483 13 p.

The Ras-related protein Rheb is farnesylated and antagonizes Ras signaling and transformation

Clark, G. J., Kinch, M. S., Rogers-Graham, K., Sebt, S. M., Hamilton, A. D. & Der, C. J., Apr 18 1997, In: Journal of Biological Chemistry. 272, 16, p. 10608-10615 8 p.

E-Cadherin Engagement Stimulates Tyrosine Phosphorylation

Kinch, M. S., Petch, L., Zhong, C. & Burrridge, K., 1997, In: Cell Communication and Adhesion. 4, 6, p. 425-437 13 p.

Rho-stimulated contractility contributes to the fibroblastic phenotype of Ras-transformed epithelial cells

Zhong, C., Kinch, M. S. & Burrridge, K., 1997, In: Molecular Biology of the Cell. 8, 11, p. 2329-2344 16 p.

Overexpression of the Ras-related TC21/R-Ras2 protein may contribute to the development of human breast cancers

Clark, G. J., Kinch, M. S., Gilmer, T. M., Burrridge, K. & Der, C. J., 1996, In: Oncogene. 12, 1, p. 169-176 8 p.

Activation of Rac1, RhoA, and mitogen-activated protein kinases is required for Ras transformation

Khosravi-Far, R., Soltski, P. A., Clark, G. J., Kinch, M. S. & Der, C. J., Nov 1995, In: Molecular and Cellular Biology. 15, 11, p. 6443-6453 11 p.

Tyrosine phosphorylation regulates the adhesions of ras-transformed breast epithelia

Kinch, M. S., Clark, G. J., Der, C. J. & Burrridge, K., Jul 1995, In: Journal of Cell Biology. 130, 2, p. 461-471 11 p.

Altered adhesions in ras-transformed breast epithelial cells

Kinch, M. S. & Burrridge, K., 1995, In: Biochemical Society transactions. 23, 3, p. 446-450 5 p.

The protein tyrosine kinase p56^{lck} regulates cell adhesion mediated by CD4 and major histocompatibility complex class II proteins

Kinch, M. S., Sanfridson, A. & Doyle, C., Nov 1 1994, In: Journal of Experimental Medicine. 180, 5, p. 1729-1739 11 p.

Integrin-mediated cell adhesion activates mitogen-activated protein kinases

Chen, Q., Kinch, M. S., Lin, T. H., Burrridge, K. & Juliano, R. L., Oct 28 1994, In: Journal of Biological Chemistry. 269, 43, p. 26602-26605 4 p.

Cell adhesion mediated by CD4 and MHC class II proteins requires active cellular processes

Kinch, M. S., Strominger, J. L. & Doyle, C., Nov 1 1993, In: Journal of Immunology. 151, 9, p. 4552-4561 10 p.

Interactions of CD4 with MHC class II molecules, T cell receptors and p56^{lck}

Vignali, D. A. A., Doyle, C., Kinch, M. S., Shin, J. & Strominger, J. L., Oct 1 1993, In: Philosophical Transactions of the Royal Society B: Biological Sciences. 342, 1299, p. 13-24 12 p.

The human antiporcine cellular repertoire: In vitro studies of acquired and innate cellular responsiveness

Kirk, A. D., Li, R. A., Kinch, M. S., Abernethy, K. A., Doyle, C. & Bollinger, R. R., 1993, In: Transplantation. 55, 4, p. 924-931 8 p.

Drug treatment of panic disorder: The comparative efficacy of imipramine, alprazolam, and trazodone

Charney, D. S., Woods, S. W., Goodman, W. K., Rifkin, B., Kinch, M., Aiken, B., Quadrino, L. M. & Heninger, G. R., 1986, In: Journal of Clinical Psychiatry. 47, 12, p. 580-586 7 p.

Grants

Advanced Energy Research and Technology Center NYS Center for Excellence 2026 - 27

Kinch, M. (PI) & Bugallo, M. (PI)

NYS Department of Economic Development: \$416,000.00

04/1/26 → 12/31/26

Projects

Advanced Energy Research and Technology Center NYS Center for Excellence 2025-2026

Kinch, M. (PI)

NYS Department of Economic Development

04/1/25 → 03/31/26

Advanced Energy Research and Technology Center NYS Center for Excellence 2026 - 27

Kinch, M. (PI) & Bugallo, M. (PI)

NYS Department of Economic Development

04/1/26 → 12/31/26

Advanced Energy Research and Technology Center NYS Center of Excellence 2024 - 2025

Kinch, M. (PI) & Donnelly, P. (PI)

NYS Department of Economic Development

04/1/24 → 03/31/25

Center for Integrated Electric Energy Systems

Kinch, M. (PI), Assanis, D. (Col), Chen, S. (Col), Hwang, D. J. (Col), Khosronejad, A. (Col), Luo, F. (Col), Mahajan, D. (Col), O'Connor, D. (Col), Samuilov, V. (Col), Shamash, Y. (Col), Solovyov, V. (Col), Suchalkin, S. (Col), Tannenbaum, R. (Col), Zhang, P. (Col), Zhao, R. (Col), Zhao, Y. (Col), Zhou, Y. (Col), Donnelly, P. (PI) & Brown, A. (Col)

NYS Department of Economic Development

07/1/20 → 03/31/26

COE: CEWIT Working Capital Contract Year 3

Kinch, M. (PI) & Donnelly, P. (PI)

NYS Department of Economic Development

09/1/24 → 08/31/25

MATRC - Manufacturing and Technology Resource Consortium

Kinch, M. (PI) & Donnelly, P. (PI)

NYS Department of Economic Development

01/1/21 → 03/31/26

Office for Innovation Advanced Energy Center Conference in NYC

Kinch, M. (PI), Reeder, R. (PI), Shamash, Y. (PI), Acquaviva, J. (PI), Miller, E. (CoPI), Donnelly, P. (Col), Bugallo, M. (PI) & O'Connor, D. (Col)

Multiple Sponsors

07/1/16 → 06/30/27

Office for Innovation Conferences and Events

Kinch, M. (PI) & Bugallo, M. (PI)

Multiple Sponsors

01/1/26 → 12/31/26

Books Published

2026	Behind the Mask: The Untold Story of the Scientists Who Confronted COVID-19 (Purdue University Press, West Lafayette, IN)
2021	The Price of Health (Pegasus Books, New York)
2019	The End of the Beginning (Pegasus Books, New York)
2018	Between Hope and Fear (Pegasus Books, New York)
2016	A Prescription for Change